{"id":382875,"date":"2020-11-17T08:33:16","date_gmt":"2020-11-17T13:33:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382875"},"modified":"2020-11-17T08:33:16","modified_gmt":"2020-11-17T13:33:16","slug":"veracyte-announces-new-general-manager-structure-to-advance-global-expansion","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/","title":{"rendered":"Veracyte Announces New General Manager Structure to Advance Global Expansion"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Veracyte Announces New General Manager Structure to Advance Global Expansion<\/b><\/p>\n<p class=\"bwalignc\"><i>John Hanna appointed GM, endocrinology, breast cancer and lymphoma;<\/i><\/p>\n<p class=\"bwalignc\"><i>Morten Frost to join company as GM, pulmonology<\/i><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=52329398&amp;newsitemid=20201117005508&amp;lan=en-US&amp;anchor=Veracyte&amp;index=1&amp;md5=d04b2bb4593ed14ffaa4edcdb08aa230\">Veracyte<\/a> (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company\u2019s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company also announced that Morten Frost will join the company as GM, pulmonology. Both executives will assume their new roles January 1, 2021.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg\" alt=\"John Hanna appointed GM, endocrinology, breast cancer and lymphoma, at Veracyte\" \/><\/p>\n<p style=\"font-size:85%\">John Hanna appointed GM, endocrinology, breast cancer and lymphoma, at Veracyte<\/p>\n<\/div>\n<p>\n\u201cVeracyte is undergoing exciting growth, including our transformation into a global diagnostics company, our growing menu of genomic tests in a range of diseases, and our planned launch next year of four new products,\u201d said Bonnie Anderson, Veracyte\u2019s chairman and chief executive officer. \u201cOur new GM-based structure will optimally position us to serve our growing customer base, manage our products throughout their life cycles to ensure long-term strategic growth and further empower our executive leaders and employees throughout the organization.\u201d\n<\/p>\n<p>\nThe new general managers will have global responsibility and accountability for their respective indications from strategic business planning to tactical execution, including pipeline development, strategy, marketing, sales, reimbursement and field-based medical affairs.\n<\/p>\n<p>\nJohn Hanna will continue to drive growth for Veracyte\u2019s flagship Afirma business in thyroid cancer and will assume leadership over the company\u2019s growing global Prosigna business in breast cancer, which together represent approximately 90 percent of revenue today. He will also lead the company\u2019s lymphoma business, with the launch of its LymphMark subtyping test scheduled for next year. Mr. Hanna joined Veracyte in 2011 and has held several leadership roles during his tenure. Since he became chief commercial officer in 2017, the company\u2019s genomic test volume and revenue have doubled.\n<\/p>\n<p>\nMorten Frost will join Veracyte to lead its lung cancer portfolio strategy, including the launch next year of the company\u2019s nasal swab test and Percepta Atlas, and will also drive the global introduction in 2021 of the Envisia classifier, for use in interstitial lung disease diagnosis, on the nCounter Analysis System. Mr. Frost comes to Veracyte with significant strategic consulting, sales and marketing experience. He was most recently at Agilent Technologies, where he served as head of global marketing for the company\u2019s pathology and companion diagnostics business, which are part of Agilent\u2019s approximately $1 billion Diagnostics and Genomics Group. In this role, he drove significant revenue growth, global product launches, biopharmaceutical partnerships and M&amp;A strategy.\n<\/p>\n<p>\n\u201cI could not be more pleased to have executives of John\u2019s and Morten\u2019s caliber leading our product businesses at this exciting moment in our company\u2019s growth,\u201d said Ms. Anderson. \u201cJohn\u2019s leadership has been critical to Veracyte\u2019s success to date and will be key to further driving revenue growth across multiple indications in the United States and globally. I am also thrilled that Morten is joining Veracyte to further strengthen our leadership team. He is an exceptional market strategist who will be critical to driving our pulmonology business forward, particularly in lung cancer, where we estimate our current and pipeline products target an addressable market of approximately $40 billion.\u201d\n<\/p>\n<p><b>About Veracyte<\/b><\/p>\n<p>\nVeracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company\u2019s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company\u2019s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte\u2019s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com&amp;esheet=52329398&amp;newsitemid=20201117005508&amp;lan=en-US&amp;anchor=www.veracyte.com&amp;index=2&amp;md5=d17fa02fa016c445629b7b2076a223a0\">www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).\n<\/p>\n<p><b>Cautionary Note Regarding Forward-Looking Statements <\/b><\/p>\n<p>\nThis press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) and intentions. Forward-looking statements can be identified by words such as: &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;will&#8221; and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions. Factors that may impact these forward-looking statements can be found in Item 1A \u2013 \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with the SEC on February 25, 2020 and in our Quarterly Report on Form 10-Q filed with the SEC on November 2, 2020. A copy of these documents can be found at the Investors section of our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com&amp;esheet=52329398&amp;newsitemid=20201117005508&amp;lan=en-US&amp;anchor=www.veracyte.com&amp;index=3&amp;md5=e5d0d79e841229b99fe469f5826c68a3\">www.veracyte.com<\/a>. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.\n<\/p>\n<p>\nVeracyte, Afirma, Percepta, Envisia, Prosigna, &#8220;Know by Design&#8221; and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are registered trademarks in the U.S. and selected countries. We have common law rights and pending trademark applications for LymphMark and \u201cMore About You.\u201d\n<\/p>\n<p>\nnCounter is the registered trademark of NanoString Technologies, Inc. in the United States and other countries and used by Veracyte under license.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005508r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media Contact:<br \/>\n<\/b><br \/>Tracy Morris<br \/>\n<br \/>Vice President of Corporate Communications<br \/>\n<br \/>&amp; Investor Relations<br \/>\n<br \/>650-380-4413<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:tracy.morris@veracyte.com\">tracy.morris@veracyte.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Technology Genetics Software Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/791654\/3\/Veracyte_RGB_LRG_H_registered.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/3\/John_Hanna_Photo_2-27-17.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">John Hanna appointed GM, endocrinology, breast cancer and lymphoma, at Veracyte<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839361\/3\/Morten_Frost_2020.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Morten Frost appointed GM, Pulmonology, at Veracyte<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Veracyte Announces New General Manager Structure to Advance Global Expansion John Hanna appointed GM, endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM, pulmonology SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company\u2019s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company also announced that Morten Frost will join the company as GM, pulmonology. Both executives will assume their new roles January 1, 2021. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/ John Hanna appointed GM, endocrinology, breast cancer and lymphoma, at Veracyte \u201cVeracyte is undergoing exciting growth, including &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Veracyte Announces New General Manager Structure to Advance Global Expansion&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382875","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Veracyte Announces New General Manager Structure to Advance Global Expansion - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Announces New General Manager Structure to Advance Global Expansion - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte Announces New General Manager Structure to Advance Global Expansion John Hanna appointed GM, endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM, pulmonology SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company\u2019s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company also announced that Morten Frost will join the company as GM, pulmonology. Both executives will assume their new roles January 1, 2021. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/ John Hanna appointed GM, endocrinology, breast cancer and lymphoma, at Veracyte \u201cVeracyte is undergoing exciting growth, including &hellip; Continue reading &quot;Veracyte Announces New General Manager Structure to Advance Global Expansion&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T13:33:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Announces New General Manager Structure to Advance Global Expansion\",\"datePublished\":\"2020-11-17T13:33:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/\"},\"wordCount\":1020,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201117005508\\\/en\\\/839360\\\/4\\\/John_Hanna_Photo_2-27-17.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/\",\"name\":\"Veracyte Announces New General Manager Structure to Advance Global Expansion - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201117005508\\\/en\\\/839360\\\/4\\\/John_Hanna_Photo_2-27-17.jpg\",\"datePublished\":\"2020-11-17T13:33:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201117005508\\\/en\\\/839360\\\/4\\\/John_Hanna_Photo_2-27-17.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201117005508\\\/en\\\/839360\\\/4\\\/John_Hanna_Photo_2-27-17.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Announces New General Manager Structure to Advance Global Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Announces New General Manager Structure to Advance Global Expansion - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Announces New General Manager Structure to Advance Global Expansion - Market Newsdesk","og_description":"Veracyte Announces New General Manager Structure to Advance Global Expansion John Hanna appointed GM, endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM, pulmonology SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company\u2019s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company also announced that Morten Frost will join the company as GM, pulmonology. Both executives will assume their new roles January 1, 2021. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20201117005508\/en\/ John Hanna appointed GM, endocrinology, breast cancer and lymphoma, at Veracyte \u201cVeracyte is undergoing exciting growth, including &hellip; Continue reading \"Veracyte Announces New General Manager Structure to Advance Global Expansion\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T13:33:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Announces New General Manager Structure to Advance Global Expansion","datePublished":"2020-11-17T13:33:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/"},"wordCount":1020,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/","name":"Veracyte Announces New General Manager Structure to Advance Global Expansion - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg","datePublished":"2020-11-17T13:33:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20201117005508\/en\/839360\/4\/John_Hanna_Photo_2-27-17.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-new-general-manager-structure-to-advance-global-expansion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Announces New General Manager Structure to Advance Global Expansion"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382875"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382875\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}